Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

NCT01235754 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

626

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypoactive Sexual Desire Disorder

Interventions

DRUG: transdermal testosterone gel 1%
DRUG: placebo gel

Sponsor

BioSante Pharmaceuticals